Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review.

Zask A, Verheijen JC, Richard DJ.

Expert Opin Ther Pat. 2011 Jul;21(7):1109-27. doi: 10.1517/13543776.2011.584871. Epub 2011 May 19. Review.

PMID:
21591993
2.

Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.

Lv X, Ma X, Hu Y.

Expert Opin Drug Discov. 2013 Aug;8(8):991-1012. doi: 10.1517/17460441.2013.800479. Epub 2013 May 14. Review.

PMID:
23668243
3.

ATP-competitive inhibitors of mTOR: an update.

Schenone S, Brullo C, Musumeci F, Radi M, Botta M.

Curr Med Chem. 2011;18(20):2995-3014. Review.

PMID:
21651476
4.

Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.

Chen SM, Liu JL, Wang X, Liang C, Ding J, Meng LH.

Biochem Pharmacol. 2012 May 1;83(9):1183-94. doi: 10.1016/j.bcp.2012.01.019. Epub 2012 Jan 26.

PMID:
22305748
5.

Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.

Barrett D, Brown VI, Grupp SA, Teachey DT.

Paediatr Drugs. 2012 Oct 1;14(5):299-316. doi: 10.2165/11594740-000000000-00000. Review.

6.

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.

Albert S, Serova M, Dreyer C, Sablin MP, Faivre S, Raymond E.

Expert Opin Investig Drugs. 2010 Aug;19(8):919-30. doi: 10.1517/13543784.2010.499121. Review.

PMID:
20569080
7.

PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.

Yuan J, Mehta PP, Yin MJ, Sun S, Zou A, Chen J, Rafidi K, Feng Z, Nickel J, Engebretsen J, Hallin J, Blasina A, Zhang E, Nguyen L, Sun M, Vogt PK, McHarg A, Cheng H, Christensen JG, Kan JL, Bagrodia S.

Mol Cancer Ther. 2011 Nov;10(11):2189-99. doi: 10.1158/1535-7163.MCT-11-0185. Epub 2011 Jul 12.

8.

New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).

Feldman ME, Shokat KM.

Curr Top Microbiol Immunol. 2010;347:241-62. doi: 10.1007/82_2010_64. Review.

PMID:
20549474
9.

Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.

Dienstmann R, Rodon J, Serra V, Tabernero J.

Mol Cancer Ther. 2014 May;13(5):1021-31. doi: 10.1158/1535-7163.MCT-13-0639. Epub 2014 Apr 18. Review.

10.

Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.

Poulsen A, Nagaraj H, Lee A, Blanchard S, Soh CK, Chen D, Wang H, Hart S, Goh KC, Dymock B, Williams M.

J Chem Inf Model. 2014 Nov 24;54(11):3238-50. doi: 10.1021/ci500493m. Epub 2014 Oct 23.

PMID:
25317974
11.

PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.

Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D.

Curr Oncol Rep. 2012 Apr;14(2):129-38. doi: 10.1007/s11912-012-0227-y. Review.

PMID:
22350330
12.

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, Zhang WG, Mahoney R, Gaydos C, Tardio L, Kim SK, Conant R, Curran K, Kaplan J, Verheijen J, Ayral-Kaloustian S, Mansour TS, Abraham RT, Zask A, Gibbons JJ.

Cancer Res. 2010 Jan 15;70(2):621-31. doi: 10.1158/0008-5472.CAN-09-2340. Epub 2010 Jan 12.

13.

Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.

Grunt TW, Mariani GL.

Curr Cancer Drug Targets. 2013 Feb;13(2):188-204. Review.

PMID:
23215720
14.

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.

Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, Cole DC, Ellingboe J, Ayral-Kaloustian S, Mansour TS, Gibbons JJ, Abraham RT, Nowak P, Zask A.

Cancer Res. 2009 Aug 1;69(15):6232-40. doi: 10.1158/0008-5472.CAN-09-0299. Epub 2009 Jul 7.

15.

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Wu P, Hu YZ.

Curr Med Chem. 2010;17(35):4326-41. Review.

PMID:
20939811
16.

Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer.

Nelson V, Altman JK, Platanias LC.

Expert Opin Investig Drugs. 2013 Jun;22(6):715-22. doi: 10.1517/13543784.2013.787066. Epub 2013 Apr 2. Review.

PMID:
23544840
17.

Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer.

Zhang X, Li XR, Zhang J.

Curr Cancer Drug Targets. 2013 Feb;13(2):175-87. Review.

PMID:
23215724
18.

Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.

García-Echeverría C.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4308-12. doi: 10.1016/j.bmcl.2010.05.099. Epub 2010 Jun 1. Review.

PMID:
20561789
19.

Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2.

Dienstmann R, Rodon J, Markman B, Tabernero J.

Recent Pat Anticancer Drug Discov. 2011 May;6(2):210-36. Review.

PMID:
21294710
20.

The mTOR protein as a target in thyroid cancer.

Souza EC, Ferreira AC, Carvalho DP.

Expert Opin Ther Targets. 2011 Sep;15(9):1099-112. doi: 10.1517/14728222.2011.594044. Epub 2011 Jun 25. Review.

PMID:
21702716

Supplemental Content

Support Center